Boehringer Ingelheim sales and marketing update
The German Institute for Quality and Efficiency in Health Care (IQWiG) said Vargatef nintedanib from Boehringer in combination with docetaxel has “minor added benefit” in adults with advanced non-small cell lung cancer (NSCLC) of the glandular tissue who have received chemotherapy and do not have brain metastases. In patients with brain metastases, the combination “had more disadvantages” than chemotherapy and docetaxel alone. Vargatef is a small molecule inhibitor of multiple pro-angiogenic kinases, including VEGF, platelet derived growth factor receptor (PDGFR) and fibroblast growth factor (FGF) receptor (FGFR). Vargatef in combination with docetaxel is approved in Europe to treat locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy (see BioCentury, Jan. 5). ...